Literature DB >> 15246371

Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper.

Erik D Brady1, Hyun-Soon Chong, Diane E Milenic, Martin W Brechbiel.   

Abstract

A simple, non-radioactive method for the determination of ligand-to-protein ratio (L/P) for novel ligand-antibody conjugates has been developed based on an exchange equilibrium with the purple Cu(II) complex of arsenazo III. The method requires a UV/Vis spectrometer and has been verified for monoclonal antibody Herceptin conjugates of a variety of ligand modalities, including common macrocyclic compounds NOTA and TETA, and with a new bifunctional tachpyridine (1H-Pyrrole-1-butanamide,N-[4-[[(1alpha,3alpha,5alpha)-3,5-bis[(2-pyridinylmethyl)amino]cyclohexyl](2-pyridinylmethyl)amino]butyl]-2,5-dihydro-2,5-dioxo-(9CI)). The spectroscopically derived values for L/P were verified by titration of the ligand-antibody conjugate with 64Cu. In each case, the value obtained by UV/Vis spectroscopy matches that found by radiolabeling. The method is rapid, taking less than 30 minutes with each ligand in this study. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246371     DOI: 10.1016/j.nucmedbio.2004.04.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  8 in total

1.  Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications.

Authors:  Hyun A Song; Chi Soo Kang; Kwamena E Baidoo; Diane E Milenic; Yunwei Chen; Anzhi Dai; M W Brechbiel; Hyun-Soon Chong
Journal:  Bioconjug Chem       Date:  2011-05-23       Impact factor: 4.774

2.  Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.

Authors:  Chi Soo Kang; Hyun A Song; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel; Hyun-Soon Chong
Journal:  Nucl Med Biol       Date:  2013-03-27       Impact factor: 2.408

Review 3.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

Review 4.  Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with 90Y or 177Lu.

Authors:  Urszula Karczmarczyk; Agnieszka Sawicka; Piotr Garnuszek; Michał Maurin; Wioletta Wojdowska
Journal:  J Med Chem       Date:  2022-04-20       Impact factor: 8.039

5.  Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.

Authors:  Hyun-Soon Chong; Hyun A Song; Xiang Ma; Diane E Milenic; Erik D Brady; Sooyoun Lim; Haisung Lee; Kwamena Baidoo; Dengfeng Cheng; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2008-06-20       Impact factor: 4.774

6.  Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development.

Authors:  Ravindra A De Silva; Sandeep Jain; Kimberly A Lears; Hyun-Soon Chong; Chi Soo Kang; Xiang Sun; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-06-27       Impact factor: 2.408

7.  A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions.

Authors:  Gabriele Caviglioli; Marco Chinol; Sara Baldassari; Lucia Garaboldi; Guendalina Zuccari; Andrea Petretto; Giuliana Drava; Chiara Sinico; Giovanni Paganelli
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

8.  Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.

Authors:  Mythili Kameswaran; Usha Pandey; Ashutosh Dash; Grace Samuel; Meera Venkatesh
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.